5 results match your criteria: "Department of Clinical Oncoproteomics[Affiliation]"

Persistence of bla-producing Proteus mirabilis in two gull colonies at a 1-year interval in Southern France.

J Glob Antimicrob Resist

June 2017

Centre Hospitalier Régional Universitaire (CHRU) de Montpellier, Département de Bactériologie-Virologie, Montpellier, France; Université Montpellier 1, Montpellier, France; INSERM U 1058, Infection by HIV and by Agents with Mucocutaneous Tropism: from Pathogenesis to Prevention, Montpellier, France.

View Article and Find Full Text PDF

High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso.

Front Microbiol

September 2016

Département de Bactériologie-Virologie, Centre Hospitalier Universitaire de MontpellierMontpellier, France; Université de MontpellierMontpellier, France; Institut National de la Santé et de la Recherche Médicale U1058, Infection by HIV and by Agents with Mucocutaneous Tropism: From Pathogenesis to PreventionMontpellier, France.

The objectives of the present study were to investigate the rate of S.aureus nasal carriage and molecular characteristics in hospital and community settings in Bobo Dioulasso, Burkina Faso. Nasal samples (n = 219) were collected from 116 healthy volunteers and 103 hospitalized patients in July and August 2014.

View Article and Find Full Text PDF

Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection.

PLoS One

June 2015

Department of Biopathology, CHU Montpellier, Montpellier, France; University of Montpellier I, Montpellier, France; Department of Clinical Oncoproteomics, Montpellier Cancer Institute (ICM), Montpellier, France.

The inhibitors of mutant BRAF that are used to treat metastatic melanoma induce squamoproliferative lesions. We conducted a prospective histopathological and molecular study on 27 skin lesions from 12 patients treated with vemurafenib. Mutation hot spots in HRAS, NRAS, KRAS, BRAF, and Pi3KCA were screened.

View Article and Find Full Text PDF

Use of autoantibodies to detect the onset of breast cancer.

J Immunol Res

May 2015

Department of Biopathology, CHU Montpellier, 34295 Montpellier Cedex 5, France ; University of Montpellier I, 34000 Montpellier, France ; Montpellier Cancer Institute (ICM), Department of Clinical Oncoproteomics, 34298 Montpellier Cedex 5, France.

The widespread use of screening mammography has resulted in increased detection of early-stage breast disease, particularly for in situ carcinoma and early-stage breast cancer. However, the majority of women with abnormalities noted on screening mammograms are not diagnosed with cancer because of several factors, including radiologist assessment, patient age, breast density, malpractice concerns, and quality control procedures. Although magnetic resonance imaging is a highly sensitive detection tool that has become standard for women at very high risk of developing breast cancer, it lacks sufficient specificity and costeffectiveness for use as a general screening tool.

View Article and Find Full Text PDF

A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.

Cancer Epidemiol Biomarkers Prev

September 2014

CHU Montpellier, Arnaud de Villeneuve, Department of Biopathology, Montpellier, France. University of Montpellier I, Montpellier, France. CRLC Val d'Aurelle, Department of Clinical Oncoproteomics, Montpellier, France.

Background: The sensitivity of mammography for the detection of small lesions, including node-negative early-stage (T1N0) primary breast cancer (PBC) and ductal carcinoma in situ (DCIS), is significantly decreased in young patients. From a clinical standpoint, an inconclusive mammogram reflects the inability of clinicians to confidently decide whether patients should be referred for biopsy or for follow-up with repeat imaging.

Methods: Specific ELISAs were developed for a panel of 13 well-recognized breast autoantigens (HSP60, FKBP52, PRDX2, PPIA, MUC1, GAL3, PAK2, P53, CCNB1, PHB2, RACK1, RUVBL1, and HER2).

View Article and Find Full Text PDF